Marjot T, Buescher G, Sebode M, et al. - In patients suffering from autoimmune hepatitis (AIH), researchers analyzed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection course. They used three international reporting registries to integrate data for patients with AIH and SARS-CoV-2 infection. They compared the results with those suffering from chronic liver disease of other etiology (non-AIH CLD) and with cases without liver disease (non-CLD). They included data for 932 patients with CLD and SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). In terms of rates of major outcomes (including hospitalization, ICU admission, and death), no differences existed between AIH and non-AIH CLD. Age, Child-Turcotte-Pugh (CTP) class B, and CTP-C cirrhosis, but not use of immunosuppression, were identified as factors related to death within the AIH cohort. Overall, findings revealed no increased risk of adverse outcomes in AIH patients despite immunosuppressive treatment vs other causes of CLD and vs matched cases without liver disease.